Dr. Fairman coordinates and directs research collaborations employing the Juvaris immunostimulatory and vaccine platforms. In this capacity, he has established a number of collaborations involving viral diseases, i.e., Influenza (Stanford), PuntaToro Virus (Utah State Univ. Anti-Viral Research Institute), Hepatitis B Virus (Utah State Univ.), and Human Immunodeficiency Virus (National California Primate Research Center, Davis); bacterial diseases, i.e., Francisella tularensis (Colorado State Univ.); and cancers (AML, Penn State), and metastatic melanoma (CSU). Dr. Fairman has also been conducting basic research on characterizing and standardizing aspects of the CLDC products and is PI on several SBIR/STTR grants and was recently awarded a U01 cooperative product development agreement for adjuvant development by NIAID. Total grant awards to Juvaris to date are over $12 million.
Entrepreneurs are constantly faced with the dilemma of funding early stage research and development in the start-up biotech environment. Given some patience and a little seed funding, the scientist/entrepreneur has access to many funding sources from government grants and contracts. The best part is the funding is non-dilutive (for founders the best kind) and comes with very little reach through on resulting intellectual property. Come listen to the experience of a scientist/entrepreneur of one start-up, Juvaris BioTherapeutics, that went from small grants of $160K to large proposals of ~$9 million which resulted in the attention of venture capital and eventual funding by Kleiner Perkins Caufield & Byers Pandemic and BioDefense Fund.
